Sunitinib resistance in renal cell carcinoma
<p>Of the many targeted therapies introduced since 2006, sunitinib has carved its way to become the most commonly used first-line therapy for the treatment of metastatic renal cell carcinoma (RCC). Despite significant improvements in progression-free survival, 30% of the patients are intrinsic...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Codon Publications
2014-04-01
|
| Series: | Journal of Kidney Cancer and VHL |
| Subjects: | |
| Online Access: | http://jkcvhl.com/index.php/jkcvhl/article/view/7 |